Treatment of migraine
AssigneeAllergan Pharmaceuticals International Limited
InventorsJoel M. Trugman, Michelle Finnegan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.
Claims30
A method of prophylactically treating migraine, the method comprising administering atogepant or a pharmaceutically acceptable salt thereof in an amount of 10 mg QD, 30 mg QD, or 60 mg QD.
A method of preventing migraine in a patient having fewer than fifteen migraine days per month, the method comprising administering atogepant in an amount of 10 mg QD, 30 mg QD, or 60 mg QD, wherein administering atogepant results in a reduction in mean monthly migraine days of at least about 3.6 days.
A method of preventing migraine, the method comprising administering atogepant in an amount of about 10 mg QD, about 30 mg QD, or about 60 mg QD, wherein administration of atogepant results in an improvement in ability to perform daily activities as compared to a pre-treatment baseline or a patient not receiving atogepant.
A method for the preventive treatment of migraine in patients having fewer than fifteen migraine days per month, the method comprising administering atogepant in an amount of 30 mg QD or 60 mg QD for at least about 12 weeks, wherein administration of atogepant results in a reduction in body weight of at least about 0.4 kg.
Dependencies are inferred from the claim text.